Eli Lilly (LLY) Stock: Pharma Giant Eyes €15 Billion French Buyout

TLDR

• Eli Lilly preparing €15 billion acquisition offer for French biotech Abivax, awaiting French Finance Ministry guidance
• Tirzepatide generated $24.8 billion revenue in first nine months of 2025, becoming world’s best-selling drug
• Orforglipron oral weight loss treatment under priority review with decision expected by February 2026
• Retatrutide achieved 28.7% mean weight loss in phase 3 trials, highest industry performance recorded
• Stock trades at 33 times forward earnings with P/E-to-growth ratio of 0.98

Eli Lilly is preparing a €15 billion acquisition offer for French biotech company Abivax. The pharmaceutical company has not submitted a formal proposal yet.

Eli Lilly and Company, LLY

The deal requires guidance from the French Finance Ministry first. Eli Lilly needs clarity on foreign investment control requirements before proceeding with an official bid.

The potential acquisition would expand Eli Lilly’s European biotech operations. The company continues generating strong revenue from its weight loss and diabetes portfolio.

Tirzepatide produced $24.8 billion in revenue through the first nine months of 2025. The drug surpassed Keytruda to become the world’s best-selling medicine.

Sold as Mounjaro for diabetes and Zepbound for obesity, tirzepatide shows no signs of slowing. Analysts forecast sales could reach $62 billion by 2030.

Eli Lilly reached a $1 trillion market cap in 2025. The company became the first healthcare firm to hit this milestone.

Oral Weight Loss Drug Nears Approval

Orforglipron represents Eli Lilly’s next major product launch. The oral weight loss and diabetes candidate completed phase 3 trials successfully.

Regulators granted the drug a priority review voucher. This designation shortens the review period from 10-12 months to just one or two months.

Eli Lilly expects an approval decision by the end of February 2026. Orforglipron is already under regulatory consideration.

Competition in weight loss treatments continues growing. Novo Nordisk recently approved the first oral weight loss pill.

Amgen and Pfizer are also developing competing products. Eli Lilly’s clinical data remains industry-leading.

Record Weight Loss Results Achieved

Retatrutide delivered 28.7% mean weight loss at the highest dose in phase 3 trials. No other weight loss treatment has matched this performance.

The results strengthen Eli Lilly’s dominance in obesity medications. Tirzepatide has also gained approval for obstructive sleep apnea treatment.

These additional indications expand market opportunities. The drug’s versatility supports continued revenue growth.

Eli Lilly stock trades at 33 times forward earnings. The healthcare sector average is 18.2 times forward earnings.

The company’s P/E-to-growth ratio stands at 0.98. This suggests undervaluation despite premium pricing.

Strong revenue and earnings growth justify the higher valuation. The pipeline supports continued expansion expectations.

Eli Lilly maintains multiple growth catalysts heading into 2026. Tirzepatide sales keep climbing while new treatments near launch.

The company awaits French regulatory guidance on the Abivax acquisition. Eli Lilly will submit its €15 billion offer after receiving formal direction from the French Finance Ministry.